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Abstract Chronic migraine (CM) is a disabling neuro-
logical condition affecting 0.5–2 % of the population. In
the current third edition of the International Classification
of Headache Disorders, medication overuse is no longer an
exclusion criterion and CM is diagnosed in patients suf-
fering from at least 15 headache days per month of which
at least eight are related to migraine. CM is difficult to
treat, and preventive treatment options are limited. We
provide a pathogenetic model for CM, integrating the latest
findings from neurophysiological and neuroimaging stud-
ies. On behalf of the Belgian Headache Society, we present
a management algorithm for CM based on the international
literature and adapted to the Belgian situation. Pharmaco-
logical treatment options are discussed, and recent data on
transcranial and invasive neuromodulation studies in CM
are reviewed. An integrated multimodal treatment pro-
gramme may be beneficial to refractory patients, but at
present, this approach is only supported by a limited
number of observational studies and quite variable between
centres.
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Definition, clinical characteristics and comorbidities
of chronic migraine
Chronic migraine (CM) is a disabling neurological condition
that only recently gained separate classification status. In the
International Classification of Headache Disorders second
edition (ICHD-2) of 2004, CM was defined as a complication
of episodic migraine (EM) with the patient suffering from at
least 15 migraine days per month for at least 3 months in the
absence of medication overuse [1]. In 2006, appendix criteria
were published to broaden the concept of CM: the patient
experiences at least 15 headache days per month, of which at
least 8 days are migraine (migraine criteria are fulfilled or
headache has been successfully treated with migraine-spe-
cific treatment), and there is no overuse of acute treatment [2].
In July 2013, the beta version of the ICHD-III was published,
including adapted CM criteria: medication overuse is no
longer an exclusion criterion (Table 1) [3].
Observational studies—including the International
Burden of Migraine Study (IBMS) [4], the American
Migraine Prevalence and Prevention (AMPP) study [5] and
the German Headache Consortium study [6]—have pro-
vided data on differences in symptom and comorbidity
profiles of CM versus EM. The relationship between EM
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and CM is complex and dynamic: approximately 2.5–3 %
of EM patients per year evolve into a CM state, a process
generally referred to as ‘‘progression’’ [7, 8]. However, CM
can remit back to EM, with a 2-year remission rate of
around 25 % in the AMPP [9].
The mean age of CM patients in the AMPP study and
IBMS was similar to that of EM patients, both most common
in females in their fourth decade of life [4, 10]. However, CM
patients had longer attacks (both treated and untreated) than
EM patients [4, 10], and CM patients are more likely to
experience severe pain intensity [4]. CM patients are more
disabled and have a lower quality of life than EM patients, as
illustrated by a lower score on the Migraine-Specific Quality
of Life (MSQ) questionnaire [4], and higher scores on the
Headache Impact Test-6 (HIT-6) [5] or Migraine Disability
Assessment (MIDAS) questionnaire [11].
CM is associated with a wide range of psychiatric and
somatic comorbidities, more so than EM. Up to 25 % of
migraineurs meet criteria for mood and/or anxiety disorders
[12]. In the AMPP study, CM patients were almost twice as
likely as EM patients to meet the criteria for depression, and
similar results were seen in the IBMS [4, 5]. A similar
distinction between EM and CM is seen with respect to
anxiety disorders [12]. It has also been suggested that post-
traumatic stress disorder occurs at a significantly higher rate
in persons with CM than in EM [13], which may be
explained in a subgroup of patients by childhood maltreat-
ment [14]. CM patients tend to have a higher Body Mass
Index than EM patients, and around 25 % of CM patients
are obese [6]. CM patients suffer more than twice as fre-
quent (around 30 % of patients) from chronic non-headache
pain disorders as compared to EM patients [10]. Respiratory
disorders and cardiac risk factors—including hypertension,
diabetes mellitus and high cholesterol—were also signifi-
cantly more reported by CM patients in the AMPP [10]. CM
patients are less likely to be full-time employed and are
more likely to be occupationally disabled [10].
A pattern thus emerges that EM and CM not only differ
in the degree of headache frequency or severity, but
diagnostic vigilance is warranted with respect to psychi-
atric and medical comorbidities which may further increase
disability [11], reduce quality of life [15] and inflate
healthcare costs [16].
Differential diagnosis of chronic migraine
CM has to be differentiated from secondary headaches as
well as from other chronic primary headache syndromes
such as hemicrania continua (HC), new daily persistent
headache and chronic tension-type headache (CTTH).
According to ICDH-III Beta, medication overuse headache
(MOH) is considered as a supplementary and not as a
differential diagnosis in patients with CM [3].
The list of secondary headaches that can mimic or
resemble CM is large, and a detailed description is beyond
the scope of this review. We should take them into con-
sideration if there are atypical features, other neurological
complaints or an abnormal clinical examination. In this
case, a brain MRI is often needed, sometimes comple-
mented by blood and CSF analysis or MR angiography.
A special attention should be given to cervicogenic head-
ache and sinus headache for which CM is often misdiagnosed
[17]. For the diagnosis of cervicogenic headache, evidence is
needed that a disorder within the cervical spine or soft tissues of
the neck, known to be able to cause headache, is present, as
well as proof of a causal relation by temporal association,
provocative manoeuvres or a diagnostic blockade [3]. Also for
sinus headache, not only proof of presence but also proof of
causality is needed. The presence or absence of purulent nasal
discharge can be of help here to differentiate [3].
HC is a strictly unilateral, constant headache with short
lasting superimposed attacks, accompanied by either auto-
nomic signs or a sense of restlessness or agitation, or aggra-
vation of the pain by movement. An absolute response to a
therapeutic dose of indomethacin is mandatory [3]. So in case
of doubt, a trial with indomethacin should be considered to
exclude this entity [18]. The other trigeminal autonomic
cephalalgias are less often a diagnostic problem because they
mainly present with short lasting headaches of less than 4 h.
New daily persistent headache persists for more than
3 months and is daily from its onset that is in general
clearly remembered. The pain lacks characteristic features
and may be migraine-like or tension-type-like, or have
elements of both [3].
CTTH is the only primary headache with prevalence as
high as that of CM, which is around 2 % according to
population-based studies [19]. Its defining criteria are
mirrored in the sense that CTTH is defined as a headache
that lacks migrainous features.
As mentioned, MOH has now to be understood as a
supplementary diagnosis, so we should consider CM with
Table 1 ICHD-III beta criteria for chronic migraine
A. Headache (tension-type-like and/or migraine-like) on C15 days
per month for [ 3 months
B. Occurring in a patient who has had at least five attacks fulfilling
criteria for migraine without aura and/or migraine with aura
C. On C8 days per month for [3 months, fulfilling any of the
following:
Criteria for migraine without aura
Criteria for migraine with aura
Believed by the patient to be migraine at onset and relieved by a
triptan or ergot derivative




MOH and CM without MOH [3]. In earlier versions of the
ICHD, a treatment of MOH by discontinuation of the
overused substance was needed, before the diagnosis of
CM could be retained. Now both can be diagnosed and also
be treated in parallel [20].
Epidemiology of chronic migraine
A whole range of criteria…
Data about the prevalence and the incidence of CM depend
on the criteria used in the population studies published
during the last 20 years. As mentioned above, the defini-
tion and the criteria changed over this period. In the first
edition of the International Classification of Headache
Disorders (ICHD-1 1998), CM was not mentioned. The
Silberstein–Lipton (S-L) criteria for transformed migraine
(1994) provided a practical definition: daily or almost daily
headache (C15 days/month) for C1 month; history of EM
and current headache still meeting ICHD-1 criteria for
migraine. The S-L criteria did not exclude medication
overuse, providing definitions of transformed migraine
with and without medication overuse.
The ICHD-2 (2004) provided a definition of CM as a
complication of migraine and required that migraine be
present for C15 days per month in the absence of medi-
cation overuse [1]. Very few patients met these stringent
diagnostic criteria. To address this, the International
Headache Society published in 2006 revised criteria [2].
The ICHD-2R criteria define CM as headache occurring on
C15 days per month with C8 days of migraine per month
for at least 3 months, in the absence of medication overuse.
…still interesting results…
In seven studies using the S-L or almost equivalent criteria,
the prevalence of CM ranged from 0.9 to 5.1 %. Three
studies based on the stringent ICHD-2 resulted in a much
lower prevalence of 0–0.7 %. At present there are no
studies using solely the ICHD-2R criteria.
The German Headache Consortium study is a longitudinal
cohort study (9665 people) of the prevalence and incidence of
headaches within the general population (age 18–65 years) [6].
Three definitions of CM were used: with the CM definition
(equivalent to the ICHD-3 beta criteria) used in the PREEMPT
trials (see Sect. 5–management), prevalence was 0.4 %;
according ICHD-2R criteria, it was 0.5 %; and using the S-L
criteria of transformed migraine, it rose to 2 %. Coexistence of
tension-type headache (21.6, 22.2 and 29.2 % of subjects) was
different according the classification criteria (Fig. 1). Statisti-
cal analysis of demographic data demonstrated striking simi-
larities between the 3 groups. All three populations were
approximately 70 % women, average 44–46 years old, with a
mean BMI of 26. Low level of education ranged between 70
and 78 % and 43–45 % were current smokers. In this popu-
lation sample, 2.9 % of the adults suffered from chronic daily
headache (C15 days of headache per month) that encompasses
CM and other chronic primary headaches, mainly CTTH, but
also patients with medication overuse.
In the AMPP study on 162 756 people aged 12 years
and older [21], the overall prevalence of CM (using S-L
criteria) was 0.91, 1.29 % in females and 0.48 % in males.
For both genders, the adjusted CM prevalence increased
throughout adolescence, peaked in midlife and declined
after age 50. Rates of CM were highest among females in
midlife, ranging from 1.86 to 1.89 % from age 18–49
(Fig. 2). A similar pattern of increasing CM prevalence
with age was observed in males. The prevalence of CM
among adolescents (females 0.46 %, males 0.24 %) dem-
onstrates that CM can start early in life (Silberstein S.
2007). Using the S-L criteria, EM sufferers develop
transformed migraine at a rate of 2.5 % per year [7]. From
383 respondents with CM in 2005 follow-up, data were
recorded in 2006 and 2007. After 2 years, 34 % (n = 130)
had persistent CM while in 26 % (n = 100), CM
Fig. 1 CM prevalence
depending on diagnostic
criteria. Adapted from




spontaneously remitted. Predictors of remission included
lower baseline headache frequency (15–19 versus 25–31
headache days/month; odds ratio [OR] 0.29) and absence
of allodynia (OR 0.45) [9, 22].
In a Taiwanese school cohort study of 3 342 adolescents
aged 13–14 years, 63 subjects (21 boys/42 girls) developed
incident chronic daily headache with an incidence rate of 1.13
per 100 PYs, including 37 with CM (0.66 per 100 PYs) and 22
with CTTH (0.39 per 100 PYs). A baseline diagnosis of
migraine (52 %) and obesity were significant predictors for both
CM and chronic daily headache. Female gender was a signifi-
cant predictor for both CTTH and chronic daily headache [23].
…and important conclusions
From these epidemiological studies, we can conclude that
CM is a relative frequent condition occurring in 0.5–2 % of
the general population. The prevalence is 2.5 fold higher in
females compared to males from age 18–55 years, with a
less important gender difference in adolescents and after
age 55 (Figs. 1, 2).
A baseline diagnosis of frequent migraine is a significant
predictor for CM. CM patients frequently overuse triptans
and/or analgesics, which favours headache chronification
and leads to MOH. After cessation of medication overuse,
remission from CM to EM occurs in about half of patients.
In CM subjects without medication overuse, reversal to EM
may also occur spontaneously.
Chronic migraine pathophysiology
The Janus face of chronic migraine
The transformation of EM to CM is characterized by a
marked increase in frequency of typical migraine attacks,
but also by frequent interval headaches without obvious
migrainous features. CM is thus a chronic pain disorder
where migraine attacks coexist with almost daily head
pain. In CM pathophysiology, one may thus expect to find
features that belong to the migraine attack and acute head
pain, in association with others more typically found in
chronic pain disorders (Fig. 3). We will therefore briefly
summarize present knowledge and hypotheses about EM
before examining the abnormalities reported in CM and
attempting to identify among the latter those that might be
specific to CM.
Pathophysiology of Episodic Migraine, sesame
to that of chronic migraine?
EM is characterized by the cyclic recurrence of attacks,
separated by headache-free periods. It is generally accepted
that the common forms of migraine with or without aura
Fig. 2 Adjusted prevalence of
chronic migraine by sex and
age. Adapted from Buse et al.
[5]
Fig. 3 Schematic representation of the interrelationship between





are complex genetic disorders where common genetic vari-
ants set a ‘‘migraine threshold’’ that is modulated by endog-
enous and exogenous factors. The brain in EM displays
several functional and structural abnormalities between
attacks (Table 2): abnormal thickness, connectivity and/or
activation of certain cortical and subcortical areas [24–27],
increased transmitter [28] or iron content [29–31], decreased
ATP content [32, 33] and an abnormal pattern of sensory
processing [34, 35]. The latter is characterized by low
amplitude of initial responses and hyperresponsivity with
lack of habituation of late responses during repeated sensory
stimuli [36], and has been attributed to a thalamocortical
dysrhythmia caused by deficient monoaminergic control by
brain stem nuclei (review in [37]). It was hypothesized that
the combination of cortical hyperresponsivity and reduced
energy reserve may lead to rupture of metabolic homoeostasis
and activation of the trigeminovascular system, the major
pain-signalling neuronal pathway of the viscera brain, via
subcortical chemosensitive neurons and/or via induction of
cortical spreading depression waves at the cortical level [38]
(see Fig. 4).
Interestingly, just before and during the attack of EM,
the cortical response pattern to sensory stimuli normalizes
[35] and activation occurs in the hypothalamus and dorsal
upper brain stem comprising monoaminergic nuclei and
periaqueductal grey matter [39–41].
Pathophysiology of chronic migraine: what is specific
to migraine, and not common with chronic pain?
The major changes found in recent electrophysiological
and imaging studies in CM are listed in Table 2. This table
also shows, for comparison, those reported in EM and in
MOH.
With electrophysiological methods, the sensory process-
ing pattern of CM is similar to that of the migraine attack, as
far as cortical responsivity is concerned, i.e. habituation
normalizes and early high-frequency oscillations increase,
reflecting thalamo-cortical activation. Hence, CM can be
compared from an electrophysiological point of view to ‘‘a
never-ending attack’’ [42, 43]. Both during an attack of EM
and in CM (between typical migraine attacks), the amplitude
of evoked potentials by low numbers of stimuli increases,
which suggests that the sensory cortices become sensitized
[43, 44]. Interestingly, the electrophysiological changes
found in CM are reversible, as shown in a MEG study of CM
patients reversing to EM [45].
A number of structural and metabolic changes have been
reported at cortical and subcortical levels in CM (see
Table 2). At present, it is not an easy task to distinguish
changes that are specific to CM from those that can be found
in other chronic pain disorders. For instance, the decrease in
tissue density and activation found in areas belonging to the
so-called pain matrix (the lateral pain system, thalamus,
insula, cingulate…) is a well-known feature in chronic pain
disorders. By contrast, connectivity changes of limbic areas
and basal ganglia might be related more closely to CM, the
more so that some of them have also been reported in EM but
not in other cephalic pains [27]. Regarding the changes in
limbic structures, one has to keep in mind, however, that
depression is a major risk factor for CM [46].
The activation found in the upper brain stem is of par-
ticular interest for two reasons. It can be found during
migraine attacks [40] as well as in CM patients in whom it
persists despite occipital nerve stimulation [47]. The upper
brain stem, probably the periaqueductal grey matter, is also
the site where tissue density is increased in MOH [48].
Overuse of analgesics and/or migraine-specific acute
medications is indeed by far the most frequent chronifying
Table 2 Brain changes in episodic migraine, chronic migraine and
medication overuse headache (recent findings with electrophysio-
logical and neuroimaging methods)
Episodic migraine (interictal)
! cortical sensitivity and % responsivity to sensory stimuli [35,
36]
% fractional anisotropy thalamus (MR-DTI) [43]
! cortical thickness and activation S1, temporal lobe [26]
% cortical thickness and/or activation insula, cingulate, visual
areas [24, 26]
% rs connectivity amygdala-insula [27]
% iron content PAG and globus pallidus [29–31]
% rs connectivity PAG-precuneus, visual [25]
% tissue density in PAG [129]
! olfaction-induced trigeminal nucleus activation
% pre-ictally [130]
% subclinical posterior circulation infarcts [30]
Chronic migraine
% cortical sensitivity and ! responsivity to sensory stimuli [26,
43, 44]
% cortical thickness and activation S1, temporal lobe
! insula, cingulate [26]
% rs connectivity limbic areas (Am, Ins, ACC)—thalamus, PAG,
midtemporal, entorhinal, S1 [131]
! rs connectivity caudate-insula; % putamen-insula [132]
% activation dorsolateral pons [47]
%% iron content PAG and globus pallidus (T2) [29, 31]
! central pain modulation [133, 134]
no % of posterior circulation infarcts [104]
Medication overuse headache
! metabolism and tissue density orbitofrontal cortex [48, 50]
! metabolism/activation of lateral pain system [50, 135]
%% cortical sensitivity depending on drug overused [49]
precuneus connectivity:! with DMN, % with hippocampus [51]




factor of EM, together with high attack frequency. In
MOH, sensory cortices become markedly sensitized
depending on the drugs overused [49], the orbitofrontal
cortex is hypometabolic [50] and atrophic [48], and con-
nectivity of the precuneus is decreased with the default
mode network, but increased with the hippocampus [51].
As in CM, some of these changes like the increase in tissue
density of the PAG are reversible in patients who succeed
in withdrawing from drugs and reverse to EM [48].
Considering the above findings and present knowledge
in EM pathophysiology, a neurophysiological model of
CM pathophysiology can be proposed (Fig. 4).
What are the implications for the management
of chronic migraine?
As suggested by clinical experience and by the reversibility
of several functional and structural brain changes, CM is
not an irreversible condition, which must be taken into
account in management decisions. CM is also not a pro-
gressive disorder in the sense that it would produce irre-
versible brain lesions, since posterior circulation
subclinical ‘‘infarcts’’ that are somewhat more frequent in
EM than in controls are not more prevalent in CM [52].
Since functional and structural changes are different in
CM compared to EM and region-specific, neuromodulation
treatments must be adapted accordingly (see 108).
In several studies, it has been shown that metabolic and
morphological brain changes in EM increase with attack
frequency [26, 29, 30]. Moreover, central sensitization that
may occur during any migraine attack becomes persistent
in CM and is thus likely to be a major chronifying factor, as
suggested by a study of cutaneous allodynia [53].
Last but not least, because of the clinical and patho-
physiological communalities between CM and chronic pain



































Fig. 4 A neurophysiological model of Chronic Migraine pathogen-
esis. The migraine headache (1) is due to activation of the
trigeminovascular system (TVS), the major pain-signalling system
in the brain. The migraine aura is caused by cortical spreading
depression (CSD) that may or may not activate the trigeminovascular
sytem. Genetic channelopathies (2) predispose to CSD in the rare
familial/sporadic hemiplegic forms of migraine (FHM). Neurophysi-
ological studies suggest that interictal abnormalities of sensory
processing due to thalamocortical dysrhythmia combined with a
decrease in the mitochondrial energy reserve may predispose the
migrainous brain to an attack, i.e. to TVS activation (3) The interictal
thalamocortical dysrhythmia favours hyperresponsivity of sensory
cortices as well as abnormal pain processing, and may be induced by
decreased control from brain stem monoaminergic nuclei. There is
evidence for upper brain stem activation during migraine attacks.
Whether this is due to collateral projections from the trigeminal
nociceptive pathway, to chemosensing of the metabolic disequilib-
rium or to input from hypothalamus and the limbic system remains to
be determined. Activation of the monoaminergic nuclei may explain
why thalamo-cortical drive increases and cortical hyperresponsivity
normalizes during an attack (4). The migraine attack is associated
with sensitization of central nociceptive pathways (5), which can be
detected by abnormalities of noxious evoked cortical and subcortical
responses. The latter abnormalities amplify in CM, where the
neurophysiological pattern is that of a « never-ending attack »; they
spread in particular to thalamic and cortical levels (6). Because of the
repeated pain attacks and possibly pre-existing comorbidities,
connectivity of limbic areas with other cortical areas (7) and the
descending pain control centres (8) is modified, which leads to
abnormal central pain control and aggravates cortical abnormalities.
Full arrowheads indicate inhibition. Grey lines indicate connections




approach, such as the one used in chronic pain disorders, is
likely to be more effective in the most disabled patients
than a single strategy [54].
Chronic migraine management
Table 3 summarizes the evidence for the various treatment
modalities used in CM.
Pharmacological treatment
Topiramate
Topiramate is one of the best-studied medications for
migraine, and its effectiveness in CM was confirmed in
several studies. The encouraging results from a small
randomized, placebo-controlled trial (RCT) of topiramate
(50 mg daily) in 28 patients with CM and medication
overuse paved the way for larger studies [58]. Two multi-
centre, parallel-group RCT in Europe (59 patients) and the
USA (328 patients) showed that topiramate at a daily dose
of 100 mg during 16 weeks was effective as a preventive
therapy for CM [59, 60]. The effect size was overall
modest, however, with a mean reduction in monthly
migraine days of 3.5 (versus placebo -0.2) and a number-
needed-to-treat of 12.5 [61]. Remarkably, the benefits of
topiramate extended to the subgroup of patients who were
overusing acute medications [62]. Topiramate use was also
associated with a decreased number of monthly days of
acute medication use (-3 days in the topiramate group
versus -0.7 days in the placebo group), but this difference
was not statistically significant. Adverse effects were mild
to moderate in severity and consistent with those noted in
previous clinical trials of topiramate: paraesthesia (num-
ber-needed-to-harm or NNH 2.4), dysgeusia (NNH 15.3),
memory disturbances (NNH 16.6), nausea (NNH 23.1) and
fatigue (NNH 31.2) [61]. No serious adverse effects were
reported, but it is known from the pooled results of RCT in
EM that one patient out of four drops out because of side
effects [63].
Sodium valproate
Valproate was found effective for chronic daily headaches,
transformed migraine or combined headaches in several
open-label studies [55, 56]. In one RCT of 70 patients (29
CM, 71 CTTH patients) [57], sodium valproate (500 mg
bid) for 3 months was superior to placebo for both general
and maximum pain levels, and headache frequency, more
so in CM than in CTTH. The number-needed-to-treat for
reduction in headache frequency was 4, but this study is
very atypical because of the complete absence of a placebo
response. Up to now, its results have not been confirmed in
a larger RCT.
Other agents
Beta blockers, methysergide, calcium antagonists, gaba-
pentin, tizanidine, amitriptyline, fluoxetine and possibly
memantine have been considered alternatives for the
treatment of CM, but evidence for their efficacy is lacking
[64].
Onabotulinum toxin type A (BoNT-A) in chronic
migraine
Botulinum toxin injections were introduced as a potential
treatment for primary headaches after the observation that
its use for cosmetic reasons could be followed by headache
improvement [65]. Although experimental studies in ani-
mals may suggest that BoNT-A is able to influence central
sensitization and nociceptive trigeminal transmission, its
precise mode of action in headaches remains unknown
[66].
A large number of RCT were performed to test the
effect of BoNT-A both in tension-type headache and
migraine. In no trial of episodic or CTTH and EM, BoNT-
A was found superior to placebo (reviewed in [67] ). Post
hoc analysis of some of those studies revealed, however,
that patients with more frequent headaches might respond
better to BoNT-A treatment.
By contrast, in CM, a meta-analysis of 5 RCT com-
prising a total of 1,508 patients (748 treated with verum,
760 with placebo) [68] shows that multiple pericranial
injections of BoNT-A induce a significantly greater
reduction of headache frequency than saline injections,
although the latter also have a beneficial effect.
The two largest multicentre RCTs were those of the
PREEMPT programme sponsored by Allergan [69] [70,
71]. PREEMPT 1 and 2 comprised 1,384 CM patients
randomized either to BoNT-A (n = 688) or to saline
injections (n = 696) and followed up for 24 weeks during
which they received two injection cycles. The double-blind
period lasted 24 weeks and was followed by an open period
of 32 weeks during which all patients received BoNT-A.
PREEMPT 1 showed no significant difference for the pri-
mary endpoint (mean reduction of headache episodes), but
secondary endpoints like reduction of headache days were
in favour of BoNT-A. Mean reduction of headache days
was therefore chosen as primary endpoint for PREEMPT 2
and for the pooled results [69]. BoNT-A was significantly
superior over saline in mean reduction of headache days at
each time points (from week 4 to week 24 primary end-
point: -8.4 BoNT-A versus -6.6 placebo; p \ 0.001;















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of moderate or severe headache days (p \ 0.001), of
cumulative hours of headache days (p \ 0.001), of head-
ache episodes (p = 0.009), of migraine episodes
(p = 0.004) and of patients with a severe (C60) HIT-6
score (p \ 0.001). At week 24, the 50 % responder rate (%
of patients with C50 % decrease in the headache days) was
47.1 % in the BoNT-A group compared to 35.1 % in the
placebo group ((p \ 0.001). The number-needed-to-treat
for BoNT-A was estimated at eight for reduction in head-
ache days [61]. Both groups were similar in reduction of
acute medication intake (p = 0.247), but a post hoc ana-
lysis revealed significantly less triptan use at week 24 in the
BoNT-A group than in the saline group (p \ 0.001).
Adverse events occurred in 62.4 % of patients treated
with BoNT-A compared to 51.7 % in those injected with
saline, most of them being mild to moderate in severity.
The discontinuation rate due to adverse events was low in
both groups (3.8 % for BoNT-A, 1.2 % for saline).
The results of the PREEMPT studies appear promising for
the most severely disabled population of migraine patients.
However, they may not be transposable without reservation
to clinical practice for the following reasons. Though statis-
tically significant, the difference between BoNT-A and pla-
cebo outcomes is in fact modest. The high response to saline
injections is a common observation in all BoNT-A studies. It
could be due to the pericranial needling, the repetition of
treatments, the direct observation of the procedure by the
patients, their awareness that the drug is expensive and/or the
cosmetic effect of clearing forehead wrinkles [72]. A recent
review confirmed that physical treatments in general are
associated with greater placebo effects than oral pharmaco-
logical treatments in migraine prevention [73]. In the PRE-
EMPT studies, approximately 65 % of patients overused
acute headache drugs at baseline. However, the treatment
response was the same in patients without and with medica-
tion overuse, regarding primary and secondary endpoints.
The patient population in the PREEMPT programme com-
prised about 40 % of subjects who never received a pre-
ventive drug treatment despite a CM history of almost
20 years and is therefore at odds with the usual phenotype of
chronic migraineurs. It is surprising that in patients naı¨ve to
BoNT-A, the placebo response was higher and the reduction
of headache days between placebo and BoNT-A groups was
not significant (-9.2 versus -8.3; p = 0.197) while BoNT-A
was superior in BoNT-A non-naı¨ve patients (7.9 versus -5.6;
p \ 0.001) [74]. Unblinding of patients (and physicians) may
thus be a confounding factor and may have decreased the
placebo effect [73].
Only a subgroup of CM patients responds to BoNT-A
injections, estimated at 30 % in tertiary headache clinic
practice. Predictors for response to BoNT-A were not
identified in the PREEMPT programme, and hence, a
major challenge for the future is to try to identify
responders on the basis of clinical and/or pathophysiolog-
ical features. In a recent study of 81 CM patients, for
instance, high plasma levels of CGRP (and VIP) correlated
with a beneficial response to BoNT-A [75].
Meanwhile, it seems reasonable to propose BoNT-A
therapy to patients who failed on several well-conducted
preventive treatments, preferentially in a multidisciplinary
setting and after withdrawal from medication overuse.
Given the effect size in the PREEMPT studies, patients
totally satisfied with the sole BoNT-A treatment are likely
to be rare in clinical practice. The treatment is able, how-
ever, to reverse some of them from the chronic to the
episodic form of migraine, in which case, other preventive
therapies can become beneficial and be added. Drug
withdrawal alone is able to achieve such reversal in ±50 %
of MOH patients. Despite the fact that in the PREEMPT
trials, outcome was not different between patients with and
without medication overuse, it seems therefore sound to
detoxify before considering BoNT-A treatment.
When there is no improvement after one series of
BoNT-A injections, a second series may recruit a propor-
tion of responders, but new responders are scarce after a
third series. One may therefore recommend abandoning
BoNT-A treatment if there is no significant improvement
of CM after the second series of injections. There is no
consensus about the total duration of BoNT-A treatment. In
the NICE guidelines—UK, it is recommended to stop
BoNT-A if a patient is improved by less than 30 % after 2
cycles of injections and when a patient has returned to the
episodic form of migraine for at least 3 months [76]. These
recommendations, however, are based on headache fre-
quency, and not intensity or duration.
Neuromodulation in chronic migraine
Due to the inefficiency of available and the lack of new
preventive anti-migraine drugs, neurostimulation methods
have raised great interest in recent years because of tech-
nological and scientific advances allowing a pathophysio-
logically based rationale in headache treatment.
Neurostimulation can be applied to peripheral (pericranial)
nerves or to central structures (the cerebral cortex). Evi-
dence supporting efficacy of these approaches in migraine
is scarce, and few RCTs are available.
Peripheral Neurostimulation (PNS)
PNS was used for a long time in neuropathic pain [77]
before being studied in headaches, first in occipital neu-
ralgia [78], and more recently in migraines.
Invasive PNS In migraine, like in other primary head-




disabled patients, i.e. those suffering from drug-resistant
CM. The best-studied technique is percutaneous greater
occipital nerve stimulation (ONS).
Occipital nerve stimulation: Besides some small and/or
heterogeneous open studies, three short-term (i.e. 3 months
each) RCT were performed in CM [79–81]. The ONSTIM
study (n = 66 patients, [80]) showed a reduction of C50 %
in headache frequency or a decrease of three points on the
intensity scale in 39 % of patients treated with active ONS
during 12 weeks, compared to no improvement in the
‘‘non-effectively’’ stimulated or medically treated groups.
Unfortunately, ONSTIM was not powered to convincingly
demonstrate effectiveness of ONS.
In the PRISM study (n = 125 patients [79]), available
only in abstract form, ONS was not superior to sham
stimulation within the 12-week assessment period.
Finally, in Silberstein et al.’s [81] ONS trial on 157
patients with CM, no difference was found between sham
and verum at the end of the 3-month treatment period for
the primary outcome measure: percentage of patients who
had C50 % reduction in mean daily headache intensity.
There was, however, a significant difference in favour of
ONS in the percentage of patients with a 30 % reduction in
mean number of headache days (p \ 0.05) and a decrease
of the MIDAS score (p \ 0.01). After the 3-month ran-
domized phase, the patients entered an open-label phase of
40 weeks [82] where after headache days had significantly
decreased in the intention-to-treat group (-6.7 days) and in
a subgroup with intractable CM refractory to preventive
drugs (-7.7 days) (p \ 0.01) This study has some serious
methodological flaws, among which not the least is that
only patients who underwent a successful trial of stimula-
tion (defined as at least 50 % reduction in pain or adequate
paraesthesia coverage in the painful areas) were perma-
nently implanted and included, which likely favoured
selection bias and unblinding.
ONS is minimally invasive, but adverse effects occur
rather frequently: lead migration [83] and battery depletion
requiring repeated surgery, local pain or infections, intol-
erance to local paraesthesia [83].
The precise mode of action of ONS in migraine is not
known. Although the initial rationale for ONS was based
on Kerr’s principle, i.e. convergence of C2 and trigemi-
novascular efferents on the spinal trigeminal nucleus [84,
85], this is not supported by experimental studies in
headache patients [86]. In chronic cluster headache, the
therapeutic response to ONS is associated with activation
of cortical pain control centres [87]. Whether this is also
the case in CM remains to be determined. Like in chronic
cluster headache where it does not modify hypothalamic
activation, ONS probably acts as a symptomatic treatment
in CM, since it is not able to normalize the activation in the
dorsal rostral pons that characterizes both migraine attacks
and CM [47]. The time to relief during ONS takes several
months, suggesting that slow modulatory effects are
involved, which contrasts with the rapid aggravation of
headaches when the battery goes flat [47, 86]. The latter
argues against a placebo effect or regression to the mean.
Combined PNS: In a retrospective study of 44 CM patients,
the combination of ONS with supraorbital nerve stimulation
(SNS) decreased headache frequency by 81 % and elimi-
nated all headaches in 50 % of patients [88]. Transcutaneous
cervical and auricular stimulators of the vagus nerve have
been developed and are being tested in migraine.
Peripheral nerve decompression: A group from the
Cleveland Clinic (USA) has proposed surgical decom-
pression of multiple pericranial nerves as a treatment
option for difficult to treat migraine patients. In a sham-
controlled trial of 75 patients suffering from ‘‘frequent to
severe migraine’’ and selected on the basis that they had a
‘‘trigger site’’ and C50 % amelioration after injection of
25U BoNT-A at this site, the therapeutic gain of surgical
decompressions over sham operation was 26 % [89].
Because of major methodological flaws in study design,
efficacy of migraine trigger site deactivation surgery in
general is at best unclear at present [90]. Potential com-
plications and high cost of the procedures further lead us to
strongly discourage migraine trigger site deactivation sur-
gery outside of the context of a clinical trial.
Non-invasive PNS The analgesic effects of TENS
(transcutaneous electrical nerve stimulation) are known
since a long time [77], and the potential benefit of TENS in
headache therapy has been suggested previously [91].
Properly designed trials, however, are lacking as pointed
out in a Cochrane review [92].
The effectiveness of a portable transcutaneous supraor-
bital nerve stimulator (tSNS) (Cefaly) in EM prophylaxis
was proven in a RCT [93] and is supported by the fact that
among 2 313 subjects in the general population who rented
the device for 60 days via internet, 53.7 % were satisfied
and decided to buy it [94]. No data are available in CM.
The modest effect size of tSNS with the Cefaly device
suggests, nonetheless, that in CM, it might at best be useful
as an add-on treatment.
New devices thought to stimulate the vagus nerve trans-
cutaneously (tVNS) were developed recently, and their effi-
cacy as acute and preventive treatment of primary headaches
is being evaluated. Preliminary results suggest that the cer-
vical stimulator could help some CM patients [95].
Central neurostimulation
Only non-invasive central neurostimulation has been used
in migraine. Mainly two methods, both able to modify




CM: repetitive transcranial magnetic stimulation (rTMS)
and transcranial direct current stimulation (tDCS) [83].
Transcranial magnetic stimulation While single TMS
pulses momentarily interrupt cortical activity and, in ani-
mal models, cortical spreading depression [96], rTMS
induces long-lasting changes: low stimulation frequencies
(i.e. 1 Hz) have an inhibitory effect [97], whereas high
frequencies (C10 Hz) are excitatory [98]. In healthy vol-
unteers and migraine patients, rTMS is able to durably
modify excitability of the visual cortex and hence to
reverse the abnormalities of evoked potentials found in
many migraineurs [99, 100].
In patients suffering from EM with aura, two single
TMS pulses over the visual cortex within an hour after aura
onset resulted in a pain-free response rate at 2 h of 39 %,
compared to 22 % for the sham stimulation [101]. It is not
known whether such a portable TMS device can be useful
as symptomatic treatment in CM.
The efficacy of rTMS for CM prevention was investi-
gated only in a few small studies. Based on the hypothesis
that the left dorsolateral prefrontal cortex (LDLPFC) is
hypoactive in chronic pain disorders, Brighina et al. [102]
studied the effect of excitatory high-frequency (20 Hz)
rTMS over the LDLPFC in 11 chronic migraineurs. After
12 sessions of rTMS, attack frequency, headache index and
acute medication intake were reduced for up to 2 months,
while there was no significant improvement in five patients
receiving the sham stimulation. These results were not
confirmed by another study where high-frequency (10 Hz)
rTMS over the LDLPFC in 13 CM patients turned out to be
less effective than placebo [103].
As mentioned in the pathophysiology section, cortical
responsivity differs between interictal EM and CM. There is
thus a rationale for a pathophysiologically guided selection of
neurostimulation procedures and protocols depending on the
migraine cycle. Using this approach, inhibitory quadripulse
rTMS were applied over the visual cortex in 16 CM patients
during a 4-week proof-of-concept trial (two rTMS sessions/
week as add-on therapy) [104] and found that monthly
migraine days decreased by 41 % (p \ 0.05) and severe
attacks by 25 % (p \ 0.05). The 50 % responder rate was
38 % and half of the patients reversed from chronic to the
EM. Clinical improvement remained stable at least 1 month
after the end of the treatment sessions. There were no adverse
events, and, interestingly, medication overuse did not modify
the response to the rTMS therapy. These results paved the
way for an ongoing sham-controlled trial.
Transcranial direct current stimulation tDCS uses weak
currents to modify the cell’s resting membrane potential,
leading to focal modulation of cortical excitability. Like in
rTMS, two opposite effects can be obtained: cathodal
stimulation inhibits neuronal firing, whereas anodal stim-
ulation increases it. In healthy volunteers, tDCS is able to
modulate resting EEG and event-related potentials [105],
and functional connectivity of corticostriatal and thala-
mocortical circuits [106], which is of particular interest for
migraine that may be associated with thalamocortical
dysrhythmia (see Sect. 4) [107].
In EM, anodal tDCS over the visual cortex (2 weekly
sessions for 8 weeks) significantly reduces attack fre-
quency and duration [108]. In 13 CM patients, anodal
tDCS over the primary motor cortex for 4 weeks produced
a beneficial delayed effect on pain intensity and duration
(120 days after stimulation) that was attributed to slow
modulation of central pain-related structures [109].
Conclusions
From the results presented above, the following provisional
conclusions can be drawn.
First, invasive ONS still awaits definitive proof of efficacy
and should only be envisaged in CM sufferers after failure or
intolerance of several preventive anti-migraine drugs and of
BoNT-A injections. In medication overuse headache
patients, it is recommended to detoxify before considering
any invasive neurostimulation, as drug overuse seems to be
associated with a less favourable outcome with ONS [110].
More trials are clearly needed to identify responders. Mean-
while, potential candidate patients for ONS must be informed
that outcome is uncertain, improvement moderate, adverse
effects inevitable and price high, unless they accept to enter a
RCT. A proportion of chronic cluster headache patients may
go into remission while being on a waiting list for surgical
intervention [83]. Assuming that this might also be the case in
CM patients, it may be wise to leave them on a waiting list for
several months before the operation.
Second, pericranial transcutaneous nerve stimulations
are unlikely to be of great benefit to CM patients because of
their modest effect size in EM. It remains to be seen
whether multisite TENS has greater effects. Among the
non-invasive neurostimulation methods, rTMS and tDCS
are the most promising for CM, and probably more so
tDCS because of its easy use and low price. Future studies
should try to adjust the stimulation protocol and site to the
migraine cycle and to the patients’ pathophysiological
profile. Large RCT is clearly needed, and they will have to
find a satisfactory way of handling the control/sham stim-
ulation and the possibility of unblinding due to the sensa-
tions generated by the neurostimulation [83, 93, 95].
Cognitive-behavioural therapy
Cognitive-behavioural therapy (CBT) defined as various




relaxation with or without biofeedback is widely used in
chronic pain disorders where it has a significant beneficial
effect. The effect size, however, is modest. In fibromyalgia
for instance, a Cochrane meta-analysis of RCT found at a
follow-up of 6 months a mean reduction of 0.6 points in
pain, 1.3 in negative mood and 1.2 in disability, all on a
0–10 scale [111].
In chronic headaches, few studies have been performed
since the report by Martin et al. [112] in 1998 showing that
a CBT designed to treat depression is more effective in
patients with high chronicity while self-management has a
better outcome when depression is low. In high-frequency
migraine (mean 5.5 migraine days/month), addition of
behavioural management alone to optimized acute treat-
ment had no significant effect, whereas the combination of
behavioural therapy with a beta blocker significantly
improved outcome at 16 months [113].
The most convincing data favouring an effect of CBT on
CM comes from trials in children and adolescents
(\18 years). A Cochrane meta-analysis of RCT (21 stud-
ies) concluded that CBT is effective in reducing headache
intensity in this patient population (mean risk ratio: 2.9 in
favour of CBT) and also improves pain and disability for
children with non-headache pain. There was limited evi-
dence, however, to estimate the effects on disability in
children [114]. A recent RCT compared the benefits of
CBT combined with amitriptyline (1 mg/kg/d) to those of
headache education with amitriptyline in 135 children and
adolescents (10–17 years old) suffering from CM. After
the 20-week randomized period, the rate of 50 %
responders for headache days was 66 % in the CBT plus
amitriptyline group versus 36 % in the other group; cor-
responding values after 12 months of follow-up were 86 %
and 69 % [115]. It is not known at present whether such
favourable results can be obtained in adult patients with
CM.
Integrated headache care
CM patients are notoriously difficult to treat. From the
review of available therapies above, it is obvious that no
single treatment modality is beneficial in more than ±30 %
of adult patients. Moreover, as mentioned, CM patients
have pathophysiological features in common with chronic
pain patients, including cognitive-behavioural patterns. In
particular, depression and anxiety, though frequently pre-
existing, usually worsen with the duration of the chronic
phase and treatment failures.
Integrated headache care is therefore proposed to the
most disabled patients in certain tertiary headache centres
[116]. It is based on a multidisciplinary and, in some cases
multimodality approach, where patients receive in various
combinations neurological care, psycho-educational
information, cognitive-behavioural relaxation therapy,
sport therapy, psychotherapy and sometimes neurostimu-
lation treatment. Most programmes are performed on an
outpatient basis; inpatient care is offered to some patients
but is rarely necessary. There is at present no uniform
format, and the modalities vary largely between centres
[116]. There is also no RCT in CM providing evidence that
integrated care is superior to other treatment modalities.
One prospective randomized trial found that a multidisci-
plinary intervention programme in episodic migraineurs
had a better outcome than standard therapy. The benefit
remained significant after a 3-month follow-up, but there
was no change in medication use or work status [117].
Two German groups have published observational pro-
spective or cross-sectional studies of headache-specific
multidisciplinary treatment programmes in recent years.
The patients included in these studies are qualified as
‘‘difficult-to-treat’’ and most of them are migraineurs, but
not all of them fulfil the criteria for CM. Overall there is a
decrease in headache frequency and headache-related dis-
ability in all studies [54, 118–120]. The 50 % responder
rate after a follow-up of 12 months varies between 36.4 %
in the largest survey of 841 patients [54] to 62.7 % in the
study by Wallasch et al. [118] of 201 patients. Interest-
ingly, in the Gaul et al. report [120], adherence varied
between treatment modalities: 35 % for drug treatment,
61 % for relaxation and 72 % for aerobic exercise. Aerobic
exercise was evaluated as such against topiramate and
relaxation in a randomized trial of EM; it achieved a 50 %
responder rate of 30 % compared to 26 and 23 %,
respectively, for the two other modalities [121].
Consensus proposal of a management algorithm
for chronic migraine
Figure 5 shows a tentative algorithm for the management
of CM. Items in bold are those for which strong evidence is
available.
The first preoccupation of clinicians taking care of
migraine patients should be to prevent chronification. This
includes optimized prophylactic treatment in patients with
frequent migraine, but also counselling on risk factors such
as excessive caffeine intake, oestrogen therapies or stress
management. To treat the acute attack of mild or moderate
severity, preference should be given to NSAIDs rather than
to analgesics because they are less prone to induce medi-
cation overuse headache [122]. It is also of uttermost
importance to manage comorbid disorders, mainly
depression and anxiety, in order to prevent an aggravating
effect on migraine and to favour the reversal from CM to
EM. This can be achieved by optimizing therapy taking
into account the effects and side effects of the respective




The major objective in the management of patients with
established CM is to reverse them to EM, which decreases
their disability and increases their responsiveness to pro-
phylactic therapies. Detoxification is mandatory in patients
with acute medication overuse, should be combined
ab initio with an adequate preventive treatment and suffices
in ±60 % of overusers. Detoxification may be achieved
through simple advice in many patients [124, 125], but in
refractory patients, specific withdrawal strategies should be
employed [20, 126].
It is common thinking that CM patients are (or have
become) resistant to available preventive treatments. This,
however, may not be assumed without reservation in many
of them because they never received ([40 % in the PRE-
EMPT trials) or never took at a sufficient dose or for a
sufficient time an established preventive drug. There is no
agreement on the number of drugs a patient should have
received before being considered refractory, but it is
common consensus that at least three or four drugs
belonging to the four most effective pharmacological
classes (beta blockers, anticonvulsants, calcium antago-
nists, tricyclic antidepressants) should have been ade-
quately tested [127]. Among these drugs, topiramate has
the strongest evidence of efficacy in CM, but the effect size
is modest (see above) and other drugs may not have been
properly studied.
Methysergide, for instance, the pioneer prophylactic
drug used in migraine prevention on the basis of the
serotonin theory, has not undergone RCT in severe or CM
because it is an old drug with a limited market. There is,
nonetheless, a consensus among the authors that
methysergide can be very useful in frequent and CM
patients refractory to the other preventives. The European
Medicines Agency (EMA), though banning all ergot
derivatives because of poor risk/benefit ratio, has recently
shared this opinion by making an exception for methyser-
gide and considering that it may have ‘‘a clinically relevant
effect in severe migraine and cluster headache’’. Its rec-
ommendations for the future use of methysergide are as
follows: restrict the drug to adult patients resistant to
standard medicines; treatment started and supervised by
specialized physicians with experience in treating
migraine; patients screened for fibrosis at baseline and
every 6 months thereafter; allow a methysergide-free per-
iod of C4 weeks every 6 months [128]. These recom-
mendations have been forwarded to the European
Commission, which will issue a final legally binding
decision in due course [128].
In patients who do not respond or are intolerant to
several preventives, alternative therapies must be consid-
ered. Among them, BoNT-A injections have at present the
best risk/benefit ratio, but, as mentioned, only a subgroup
of patients will respond. Unfortunately, no evidence-based
alternatives can be offered to those non-responders. Neur-
ostimulation methods are promising, but RCTs are needed.
For obvious reasons, non-invasive methods should be tried
before invasive ones.
There is evidence from other chronic pain disorders and
some indication from observational studies in CM that
patients who are not improved by preventive drugs and
adequate management of risk and aggravating factors do
better with integrated multimodal treatment programmes.
Manage comorbid disorders
(depression, anxiety, chronic pain…)
Use prophylactic treatment in 
high frequency migraine
Restrict acute drug consumption 
& prefer NSAIDs to analgesics
Avoid risk factors
(excess caffeine, stress, estrogens…)
Prevention
CHRONIC MIGRAINE Medication overuse






















Such programmes, however, are available only in special-
ized headache centres, and more trials are needed to
determine which are the most effective programmes and
whether they should be customized to individual patients or
patients subgroups.
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